HOME >> MEDICINE >> NEWS
Updated adjuvant data presented at SABCS show 30 percent reduction in recurrence

San Antonio, December 8 Pfizer announced today that it has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for AROMASIN (exemestane tablets) in the adjuvant treatment of postmenopausal women with estrogen receptor positive or receptor unknown early-stage breast cancer.

AROMASIN is a hormonal therapy that belongs to a class of drugs called aromatase inhibitors which work by blocking the production of estrogen, which is known to play a key role in the development and growth of breast cancer. For many years, treatment with tamoxifen has been the standard hormonal therapy for postmenopausal women with breast cancer that is dependent upon estrogen for growth. Results from the pivotal Intergroup Exemestane Study (IES), published in the New England Journal of Medicine, demonstrated that postmenopausal breast cancer patients who had been treated with 2-3 years of tamoxifen for early breast cancer (adjuvant treatment with tamoxifen) and were switched to AROMASIN significantly reduced their risk of recurrence and increased disease-free survival compared to patients who remained on tamoxifen for the entire five years.

"The adjuvant approval of AROMASIN would provide oncologists with a treatment regimen that significantly reduces the recurrence of breast cancer," said Dr. Stephen Jones, medical director at U.S. Oncology Research. "This filing is an important step toward providing postmenopausal women with a critical treatment option that can significantly improve survival of early breast cancer when compared to tamoxifen."

Pfizer's announcement closely follows newly released American Society of Clinical Oncology (ASCO) recommendations on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone-receptor-positive breast cancer and coincides with the presentation of an update on the study trial being used to support the filing. The ASCO recommendations,
'"/>

Contact: Steven Cooper
steven.cooper@edelman.com
917-301-7566
Edelman Public Relations
8-Dec-2004


Page: 1 2 3

Related medicine news :

1. Updated press release to October 2004 Cochrane Review
2. Updated data compares DOXIL (R)/CAELYX (TM) (doxorubicin HCl liposome injection) to Topotecan
3. Newly Updated HIV Treatment Guidelines For Adults And Adolescents Available On The World Wide Web
4. Updated Results On Heart Assist Device Presented At International Transplant Meeting
5. MRI better than current standard in assessing neoadjuvant chemotherapy for breast cancer
6. Neoadjuvant and adjuvant systemic therapy for breast cancer give equivalent survival, study finds
7. Different methods of adjuvant chemotherapy for colorectal cancer have similar outcomes
8. Study supports tailoring adjuvant therapy for early-stage breast cancer
9. Nordic collaboration gives new insights into adjuvant chemotherapy
10. New tipifarnib (R115777) data in AML presented at American Society of Hematology Annual Meeting
11. Elderly cancer patients are significantly under-represented in cancer clinical trials

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/31/2020)... ... August 31, 2020 , ... Ocean Springs, Mississippi-based pharmaceutical distributor ... first responders across the United States. Since the start of the global COVID-19 ... medical centers , hospitals , firefighters , and public ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... services to dental groups in the United States, today announced the grand opening ... Beaumont, CA. , Patients will enjoy convenient hours, a comfortable office, and ...
(Date:8/31/2020)... ... August 31, 2020 , ... Dr. Chang has over ... autism and other developmental disabilities, as well as supporting staff in caring for ... autism, school consultation, and staff development. She joined the company in 2015 as ...
(Date:8/28/2020)... ... August 28, 2020 , ... ... designed to help treat patients with respiratory conditions, including COVID-19, while reducing the ... and oxygen, but it captures exhaled gas and scrubs it free of carbon ...
(Date:8/28/2020)... ... , ... Ziegler, a specialty investment bank, is pleased to ... a tech-enabled behavioral health and well-being solutions provider. , Synchronous Health, a ... (AI) to increase access and quality of behavioral health services, and Adventist Health, ...
Breaking Medicine News(10 mins):
(Date:8/27/2020)... ... 27, 2020 , ... InfoMC, a leading provider of cloud-based ... 2020 System and Organizational Controls (SOC) 1® Type 2 and SOC 2® Type ... These achievements reflect their long-standing commitment to privacy, security, and risk management, while ...
(Date:8/27/2020)... Mich. (PRWEB) , ... August 27, 2020 , ... The flu season is right round ... to get well equipped with all the necessary measures before it begins to harbor its ... also increasing, and it is leaving a huge impact on our lives. Hence it has ...
(Date:8/27/2020)... ... August 27, 2020 , ... ... with Enquire, a leading provider of cloud CRM, marketing automation, and contact center ... partnership will involve the integration of Trella’s performance intelligence data and insights into ...
Breaking Medicine Technology:
Cached News: